FiteBac Pharma

FiteBac Pharma is a biotechnology company focused on the development and commercialization of a novel antimicrobial platform technology known as K21. The K21 molecule is a quaternary ammonium silane that provides persistent, non-leaching antimicrobial protection by physically disrupting the cell membranes of bacteria, fungi, and certain viruses. The company's technology is designed to be integrated into various materials, including dental composites, wound care gels, and medical device coatings, to prevent biofilm formation and reduce infection risks. FiteBac has successfully achieved FDA clearance for several products in the dental and wound care sectors and continues to expand its pipeline into broader pharmaceutical and surgical applications. By offering a non-leaching solution, FiteBac addresses critical concerns regarding antimicrobial resistance and systemic toxicity associated with traditional anti-infectives.